Verastem CEO Paterson To Retire January 1, Board Member Bailey Takes Over, 8-K Says

The CEO handoff came with a first multi-tumor data update for VS-7375 and preliminary third-quarter product revenue of $23.9 million to $24.1 million.

Share
Verastem CEO Paterson To Retire January 1, Board Member Bailey Takes Over, 8-K Says

Verastem CEO Daniel Paterson will retire effective January 1, 2027, and board member Michael Bailey, 61, will succeed him as president and CEO, according to an 8-K filed Wednesday. The company paired the handoff with early data on its KRAS G12D drug VS-7375 and preliminary third-quarter results.

The handoff

Paterson told the board on October 12 that he would retire. He intends to stay on as a Class III director, with his term running to the 2027 annual meeting, and the company expects him to serve as a consultant starting around January 1.

Bailey will remain a Class II director, with a term to the 2029 annual meeting. The filing says Bailey's pay and employment terms, and Paterson's consulting terms, will be set before the effective date and disclosed in an amendment to the 8-K.

Bailey joined Verastem's board in May 2026, per the company's release. The filing says he was AVEO Pharmaceuticals' president and CEO from January 2015 to June 2026. Paterson has been at Verastem since 2011 and CEO since 2023; the release says he led the acquisition and commercialization of the avutometinib-defactinib ovarian cancer combination and was instrumental in acquiring VS-7375.

The numbers that came with it

The 8-K carries preliminary, unaudited third-quarter net product revenue of $23.9 million to $24.1 million, against $11.2 million a year earlier. Cash, cash equivalents and investments were estimated at $172.8 million at September 30, versus $137.7 million a year earlier.

In a separate release, the company said VS-7375 at 900 mg daily produced a 41% confirmed response rate (9/22) in previously treated pancreatic cancer, including two complete responses. In second-line patients the rate was 50% (4/8). The six-month progression-free survival rate was 67%. These are early data from an ongoing Phase 1/2 trial, with a data cutoff of October 7.

In lung cancer, 600 mg monotherapy produced a 43% confirmed response rate (10/23). In colorectal cancer, 900 mg with an anti-EGFR drug showed a 33% response rate (2/6), including one unconfirmed response.

The filing also says Verastem terminated its at-the-market stock sale prospectus effective October 14, with no shares sold under it. It adds that the FDA accepted its Blister Pack new drug application for review and granted priority review.

What to watch

Verastem says it has reached alignment with the FDA on a three-arm Phase 3 design in first-line pancreatic cancer and plans to open the trial by year-end 2026. At Tuesday's close, shares stood at $7.45 after a 9.7% drop that session, before Wednesday's disclosure.

The amended 8-K with Bailey's and Paterson's terms is due before January 1, the day the handoff takes effect.

Sources

More on Verastem

All Verastem (VSTM) coverage →